**Figure e-1. Flowchart of included patients**

This flowchart documents the patients who were ultimately included in the analysis, and the

reasons for excluding certain patients.

Figure e-2. Elevated serum neuronal antibodies

The above graph lists the antibodies that were documented as elevated in patients in the study, and the testing was performed at the time of patient's clinical investigation. Of note, having an elevated antibody did not necessarily signify the patient was diagnosed with PCD. Abbreviations: Gad-65= Glutamate decarboxylase 65 antibody; P/Q-type VGCC= P/Q type voltage-gated calcium channel antibody; AChR= Acetylcholine receptor antibody; VGKC= voltage-gated potassium channel antibody; N-type VGCC= N-type voltage-gated calcium channel antibody; Hu= Anti-Hu antibody (also known as anti-neuronal nuclear antibody, type 1 (ANNA-1)

Figure e-3. Diagnostic etiologies of cases with an identified diagnosis

Inpatients

Outpatients

- Immune-mediated; Nonparaneoplastic
- Immune-mediated; Paraneoplastic
- MSA-C
- Genetic
- Vertebrobasilar
- Iatrogenic
- Other

Abbreviations: MSA-C= multiple system atrophy, cerebellar variant